Literature DB >> 9309434

Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control.

K K Lai1, Z S Melvin, M J Menard, H R Kotilainen, S Baker.   

Abstract

OBJECTIVES: To evaluate the effectiveness of specific infection control measures on the incidence of Clostridium difficile-associated diarrhea (CDAD) and to identify risk factors for its development.
SETTING: 370-bed, tertiary-care teaching hospital with approximately 12,000 to 15,000 admissions per year.
METHODS: Several infection control measures were implemented in 1991 and 1992, and the attack rates of CDAD were calculated quarterly. Antibiotic use for 1988 through 1993 was analyzed. A case-control study was conducted from January 1992 to December 1992 to identify risk factors for acquisition of CDAD.
RESULTS: From 1989 to 1992, the attack rate of CDAD increased from 0.49% to 2.25%. An increase in antibiotic use preceded the rise in the incidence of CDAD in 1991. Despite implementation of various infection control measures, the attack rate decreased to 1.32% in 1993, but did not return to baseline. Ninety-two cases and 78 controls (patients with diarrhea but with negative toxin assay) were studied. By univariate analysis, history of prior respiratory tract infections (odds ratio [OR], 3.6; 95% confidence interval [CI95], 1.2-10.4), the number of antibiotics, and the duration of exposure to second-generation cephalosporins (OR, 3.55; CI95, 1.47-9.41) and to ciprofloxacin (OR, 7.27; CI95, 1.13-166.0) were related significantly to the development of CDAD. By stepwise logistic regression analysis, only exposure to antibiotics and prior respiratory tract infections (P = .0001 and .0203, respectively) were found to be significant.
CONCLUSION: Antibiotic pressure might have contributed to failure of infection control measures to reduce the incidence of CDAD to baseline.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9309434     DOI: 10.1086/647687

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  14 in total

1.  Clarification of article on Clostridium difficile--associated colitis.

Authors:  Kenneth Brown
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

Review 2.  Reducing Clostridium difficile in the Inpatient Setting: A Systematic Review of the Adherence to and Effectiveness of C. difficile Prevention Bundles.

Authors:  Anna K Barker; Caitlyn Ngam; Jackson S Musuuza; Valerie M Vaughn; Nasia Safdar
Journal:  Infect Control Hosp Epidemiol       Date:  2017-03-27       Impact factor: 3.254

3.  Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea.

Authors:  M J Alfa; A Kabani; D Lyerly; S Moncrief; L M Neville; A Al-Barrak; G K Harding; B Dyck; K Olekson; J M Embil
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

4.  Diarrhea recurrence in patients with Clostridium difficile-associated diarrhea: Role of concurrent antibiotics.

Authors:  M Alfa; G Harding; A Ronald; R Light; N Macfarlane; N Olson; P Degagne; K Kasdorf; A Simor; K Macdonald; L Louie
Journal:  Can J Infect Dis       Date:  1999-07

5.  The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity.

Authors:  Jin Ku Kang; Jae Sam Hwang; Hyo Jung Nam; Keun Jae Ahn; Heon Seok; Sung-Kuk Kim; Eun Young Yun; Charalabos Pothoulakis; John Thomas Lamont; Ho Kim
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

6.  Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea.

Authors:  Ji Won Kim; Kook Lae Lee; Ji Bong Jeong; Byeong Gwan Kim; Sue Shin; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  World J Gastroenterol       Date:  2010-07-28       Impact factor: 5.742

7.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county.

Authors:  T Norén; T Akerlund; E Bäck; L Sjöberg; I Persson; I Alriksson; L G Burman
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

10.  High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection.

Authors:  M Komatsu; H Kato; M Aihara; K Shimakawa; M Iwasaki; Y Nagasaka; S Fukuda; S Matsuo; Y Arakawa; M Watanabe; Y Iwatani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-08-21       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.